Clinical trials
Gastric Cancer, Gastroesophageal Junction Cancer clinical trials
Below are recruiting gastric cancer, gastroesophageal junction cancer clinical trials, each written for real people, not researchers. We’re tracking 228 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07320586RecruitingPhase 2
Carilizumab and chemo for advanced gastric cancer
This trial tests a combination of carilizumab (an immunotherapy) and albumin paclitaxel (a chemotherapy drug) for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line treatment. It aims to see if this second-line option can help control the cancer.
Jinan, ShandongAges 18–75 - NCT07334431RecruitingPhase 1/Phase 2
A trial of fruquintinib, trastuzumab, and chemo for HER2-positive stomach cancer
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
Zhengzhou, HenanAges 18–75 - NCT06731478RecruitingPhase 3
New drug combo for first treatment of HER2-positive stomach cancer
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
New Haven, ConnecticutAges 18 years+ - NCT07552402Recruiting
Oral Paclitaxel Plus Fruquintinib for Advanced Stomach Cancer
This trial tests a combination of two oral drugs (paclitaxel and fruquintinib) for advanced stomach cancer that has already been treated with one round of chemotherapy. The goal is to see if this combination helps control the cancer better than other standard second-line treatments.
Harbin, HeilongjiangAges 18–75 - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Mobile, AlabamaAges 18 years+ - NCT07366528RecruitingPhase 3
Comparing two chemo combos for stage III stomach cancer after surgery
This trial compares two chemotherapy combinations (oxaliplatin plus S-1 vs docetaxel plus S-1) for people with stage III stomach cancer who have had complete surgical removal of the tumor. The goal is to see which combination works better to prevent cancer from returning.
Shaoguan, GuandongAges 18–80 - NCT07217704RecruitingPhase 3
New PET scan to find stomach or esophageal cancer spread
This trial tests a new PET scan drug (18F-FAPI) to see if it can better detect where stomach or esophageal cancer has spread. It may help doctors plan the right treatment for you.
Cerritos, CaliforniaAges 18 years+ - NCT07401199Recruiting
AI predicts immunotherapy response in advanced stomach cancer
This trial uses artificial intelligence to analyze CT scans, blood, and tumor tissue to predict how well your cancer will respond to chemotherapy and immunotherapy before surgery. It aims to personalize treatment for locally advanced stomach or gastroesophageal junction cancer.
Fuyang, AnhuiAges 18 years+ - NCT07432295RecruitingPhase 2
Givastomig plus nivolumab and chemo for advanced stomach cancer
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Goodyear, ArizonaAges 18 years+ - NCT07464470Recruiting
Comparing stomach cancer and brain metastasis genetics
This trial studies stomach and esophageal cancers that spread to the brain. It compares the genetic makeup of the original tumor to the brain metastasis, which may help find better treatments.
MoscowAges 18 years+ - NCT07481357RecruitingPhase 1
DA 3501 for advanced stomach or pancreatic cancer
This trial tests a new drug, DA 3501, in people with advanced stomach or pancreatic cancer that has a specific protein called CLDN18.2. It aims to see if the drug is safe and effective.
Seongnam, BundangAges 19 years+ - NCT07482566Recruiting
Comparing two surgeries for advanced gastroesophageal junction cancer
This trial compares two types of stomach-removing surgeries (total vs. partial gastrectomy) in people with a certain kind of advanced gastroesophageal junction cancer. The goal is to find out which surgery leads to better outcomes.
Istanbul, IstanbulAges 18–90 - NCT07492615RecruitingPhase 2
Sintilimab plus chemo vs. chemo alone for stomach cancer after surgery
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07517107RecruitingPhase 2
Blood tests to guide gastric cancer treatment decisions
This study uses special blood tests to detect cancer DNA and help doctors decide the best treatment plan for gastric cancer. The goal is to improve outcomes by personalizing therapy based on how your cancer responds.
ShanghaiAges 18 years+ - NCT07518147RecruitingPhase 3
BL-M05D1 for advanced stomach cancer after first treatment
This study tests a new antibody drug (BL-M05D1) for advanced stomach or lower esophagus cancer that did not respond to first-line chemotherapy. The drug targets a protein called claudin 18.2 found on some cancer cells and may help slow or shrink the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07551362RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Gastric Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
Shenzhen, GuangdongAges 18–75 - NCT07556640RecruitingPhase 2
Drug combination for stomach cancer with abdominal spread
This trial tests a combination of chemotherapy drugs (LM-302, S-1, and paclitaxel) with or without an immune-boosting drug (cadonilimab) for gastric cancer that has spread to the abdominal lining. The goal is to shrink tumors and improve survival in patients whose cancer cells show a specific protein marker called Claudin 18.2.
Shanghai, Huangpu DistrictAges 18 years+ - NCT07631000RecruitingPhase 2
Cadonilimab with chemotherapy for stomach cancer surgery
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. The goal is to shrink the tumor and improve outcomes for patients who are candidates for surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT07655024RecruitingPhase 2
TAIC plus FOLFOX for advanced stomach cancer
This trial tests a traditional Chinese medicine (TAIC) combined with chemotherapy (FOLFOX) for people with advanced stomach or gastroesophageal junction cancer that can't be removed with surgery. It aims to see if the combination can help shrink the tumor and improve survival.
BeijingAges 18 years+ - NCT07671625Recruiting
Prehabilitation program for esophageal or gastric cancer
This trial tests a comprehensive program that includes exercise, nutrition, and psychological support before and after surgery for patients with locally advanced esophageal or gastric cancer. It aims to improve recovery and outcomes.
BrnoAges 18 years+ - NCT07533825Enrolling by invitation
Minimally Invasive Surgery Staging for Advanced Stomach Cancer
This trial tests whether a minimally invasive camera-guided surgical procedure (laparoscopy) can better detect hidden cancer spread in patients with advanced stomach cancer. The goal is to help doctors plan the best treatment and improve outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07356466Enrolling by invitationEarly Phase 1
Combination therapy vs. standard chemo for advanced stomach cancer
This trial tests whether adding two newer drugs (pucotenlimab and lenvatinib) to standard chemotherapy (SOX) works better than chemotherapy alone for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if the combination slows cancer growth.
Fuzhou, FujianAges 18–75 - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT06767449Recruiting
Zolbetuximab for Claudin18.2 positive stomach cancer
This trial is for people with advanced stomach cancer that has a specific protein called Claudin18.2 and is HER2-negative. It tests whether continuing zolbetuximab—a drug that targets this protein—can help control the cancer.
SeoulAges 19 years+
Hear when a new Gastric Cancer, Gastroesophageal Junction Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric cancer, gastroesophageal junction cancer?
- Yes. Clin2 currently lists 228 recruiting gastric cancer, gastroesophageal junction cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric cancer, gastroesophageal junction cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric cancer, gastroesophageal junction cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal-junction Cancer
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction (GEJ) Cancer
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastric Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.